IDEAYA Biosciences, Inc. (IDYA) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
IDYA Revenue Growth
Revenue Breakdown (FY 2025)
IDYA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
IDYA Revenue Analysis (2017–2025)
As of May 8, 2026, IDEAYA Biosciences, Inc. (IDYA) generated trailing twelve-month (TTM) revenue of $225.3 million. The most recent quarter (Q1 2026) recorded $6.6 million in revenue, down 39.7% sequentially.
Looking at the longer-term picture, IDYA's 5-year compound annual growth rate (CAGR) stands at +62.1%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $218.7 million in 2025, representing a new all-time high.
Revenue diversification analysis shows IDYA's business is primarily driven by Research and Development Services (100%). With over half of revenue concentrated in Research and Development Services, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including TPVG, AGEN (+10.4% YoY), and KYMR (-12.6% YoY). Compare IDYA vs TPVG →
IDYA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| IDYACurrent | $225M | - | +62.1% | -72.8% | |
 TPVG | $97M | - | - | 77.9% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% |
IDYA Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $218.7M | +3024.4% | $214.1M | 97.9% | $-159,313,000 | -72.8% |
| 2024 | $7.0M | -70.1% | $3.2M | 45.2% | $-326,975,000 | -4671.1% |
| 2023 | $23.4M | -54.1% | $19.4M | 82.9% | $-134,429,000 | -574.9% |
| 2022 | $50.9M | +82.3% | $48.8M | 95.9% | $-62,502,000 | -122.7% |
| 2021 | $27.9M | +43.0% | $26.2M | 93.8% | $-50,268,000 | -179.9% |
| 2020 | $19.5M | - | $18.2M | 92.9% | $-35,344,000 | -180.9% |
| 2019 | $0 | - | $-1,245,000 | - | $-44,271,000 | - |
| 2018 | $0 | - | $-886,000 | - | $-36,417,000 | - |
| 2017 | $0 | - | $-391,000 | - | $-14,438,000 | - |
See IDYA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IDYA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IDYA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIDYA — Frequently Asked Questions
Quick answers to the most common questions about buying IDYA stock.
Is IDYA's revenue growth accelerating or slowing?
IDYA TTM revenue: $225M. YoY growth: N/A. 5-year CAGR: +62.1%.
What is IDYA's long-term revenue growth rate?
IDEAYA Biosciences, Inc.'s 5-year revenue CAGR of +62.1% reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is IDYA's revenue distributed by segment?
IDYA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.